Loading...
01/11 03:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed signals. Strong revenue growth and capacity expansion plans are positive, but ongoing margin pressures and supply chain issues in eye care are concerning. The Q&A session highlighted confidence in supply normalization and strategic M&A, yet lacked clarity on certain impacts and specific metrics. Considering the market cap, these factors suggest a neutral stock price movement.
Q1 Sales $250 million, a decline from the $258 million to $260 million forecasted earlier. This was due to the timing of sales orders between Q4 last year and Q1 this year, as well as a planned production shutdown in eye care that stretched longer than anticipated.
Gross Margin 56.2%, an expansion of 150 basis points year-over-year. This was attributed to ongoing cost savings efforts.
EPS (Earnings Per Share) $0.95, up approximately 6% year-over-year. The increase was due to gross margin expansion, marketing expense timing, and lower interest expense, despite a sales miss.
Free Cash Flow $78 million, a quarterly record. This was driven by the timing of working capital and disciplined debt reduction efforts.
Q1 Revenue $249.5 million, a decline of 6.6% from $267.1 million in the prior year. The decline was due to supply-constrained eye care products and the timing of certain e-commerce customer orders.
North America Segment Revenue Decreased 8.4% year-over-year, primarily due to supply-constrained eye care products and timing of orders.
International Segment Revenue Increased 7.1% year-over-year, driven by broad-based sales growth.
Advertising and Marketing Expenses $35 million or 14% of sales, down year-over-year due to the timing of marketing programs.
G&A Expenses 11.4% of sales in Q1, higher due to the timing of certain expenses.
Interest Expense $10 million, reduced due to continued debt reduction efforts.
Clear Eyes: Production shutdown in May caused significant shortfall in Q1. Acquisition of Pillar5 announced to secure and expand long-term supply.
International segment: Experienced 7% organic sales growth, driven by broad-based sales growth.
E-commerce channel: Achieved double-digit year-over-year consumption growth, continuing the trend of higher online purchasing.
Gross margin: Expanded by 150 basis points to 56.2% in Q1 due to cost savings efforts.
Free cash flow: Achieved a quarterly record of $78 million, enabling capital deployment for shareholder value.
Leverage ratio: Maintained at approximately 2.4x.
Acquisition of Pillar5: Acquired primary Clear Eyes supplier to address supply chain issues and expand capacity. Estimated purchase price of $100 million, funded from cash on hand.
Supply Chain Constraints: The company faced significant supply chain challenges, particularly in the eye care segment, leading to a production shutdown that lasted longer than anticipated. This resulted in a revenue shortfall and inability to meet customer demand.
Revenue Decline: Q1 fiscal 2026 revenues declined by 6.6% year-over-year, primarily due to supply chain issues in the eye care segment and timing of sales orders. This has impacted the company's financial performance and outlook.
Eye Care Segment Challenges: The eye care segment, particularly the Clear Eyes product line, faced production shortfalls and supply constraints. This has led to a significant revenue impact and necessitated the acquisition of Pillar5 to address long-term supply issues.
Retail Environment Headwinds: The company is experiencing lower retail order patterns, particularly in July, which are inconsistent with stable consumption rates outside of the eye care segment. This adds to the revenue challenges.
Tariff Costs: The company anticipates a full-year potential tariff cost of approximately $5 million, which could impact profitability if not offset by strategic actions.
Economic and Geopolitical Uncertainty: High inflation, geopolitical events, and economic uncertainties continue to pose risks to the business environment, potentially impacting operations and financial performance.
Revenue Guidance for Fiscal 2026: Prestige Consumer Healthcare anticipates revenues of $1.1 billion to $1.115 billion for fiscal 2026, with organic revenue expected to decline approximately 1.5% to 3% compared to the previous year. This revision is primarily due to anticipated supply constraints in the eye care segment during the first half of the fiscal year and a challenging retail environment.
Revenue Guidance for Q2 Fiscal 2026: The company expects Q2 revenues to range between $256 million and $259 million, reflecting a year-over-year decline due to Clear Eyes supply chain timing issues and lower retail order patterns observed in July.
Clear Eyes Supply Chain Recovery: Significant improvement in Clear Eyes shipments to retailers is anticipated in the second half of fiscal 2026, with a more meaningful recovery expected to extend into fiscal 2027.
Gross Margin Outlook: The company projects a gross margin of 56.5% for fiscal 2026, with Q2 gross margin expected to be 55.5%.
Earnings Per Share (EPS) Guidance: Adjusted EPS for fiscal 2026 is expected to range between $4.50 and $4.58, with Q2 EPS anticipated to be approximately $0.97.
Free Cash Flow Outlook: Prestige Consumer Healthcare maintains its outlook for free cash flow of $245 million or more for fiscal 2026.
Capital Expenditures (CapEx): The company expects CapEx to increase to 1% to 3% of sales annually, up from the previous range of 1% to 2%, due to the acquisition of Pillar5 Pharma.
Share Repurchase: In Q1, we repurchased over 400,000 shares and maintained our leverage ratio of approximately 2.4x. In the quarter, we repurchased approximately 400,000 shares for $35 million, and we'll continue to evaluate further repurchase opportunities in the remainder of fiscal '26.
The earnings call summary reflects a mix of positive and negative elements. Basic financial performance is challenged by supply chain issues and declining revenue guidance, while product development and market strategy show potential for recovery and growth. Expenses are manageable with expected cash flow, but the lack of clear guidance and uncertainties in specific areas like Clear Eyes recovery and e-commerce order patterns contribute to a neutral sentiment. Given the market cap, the stock is likely to experience minor fluctuations, resulting in a neutral prediction for the next two weeks.
The earnings call revealed mixed signals. Strong revenue growth and capacity expansion plans are positive, but ongoing margin pressures and supply chain issues in eye care are concerning. The Q&A session highlighted confidence in supply normalization and strategic M&A, yet lacked clarity on certain impacts and specific metrics. Considering the market cap, these factors suggest a neutral stock price movement.
The earnings call presents a positive outlook with projected revenue growth of 11-14%, strong organic volume growth, and successful product launches. The company anticipates record free cash flow and is pursuing a significant sale leaseback transaction. Despite some margin pressure and inventory increases, these are expected to stabilize. The Q&A reveals optimism in demand and growth initiatives, with no major risks highlighted. The market cap suggests moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
